Skip to main content
    I

    Intellia Therapeutics Inc (NTLA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $11.34
    -0.09 (-0.79%)

    Market Cap: $1.67B

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    51%(20/39)
    Avg Surprise
    -4.89%
    Streak
    8 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.79
    Range$-0.89 - $-0.71
    16 analysts
    EPS Revisions
    1
    0
    7d
    2
    0
    30d
    EPS Estimate DriftChange to current
    90d ago$-0.78-0.9%
    60d ago$-0.79+0.8%
    30d ago$-0.79+0.3%
    7d ago$-0.79+0.2%
    Current$-0.79
    Revenue Consensus
    $10M
    Range$0 - $15M
    15 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.68
    Range$-0.94 - $-0.36
    17 analysts
    Revenue Consensus
    $15M
    Range$-13846640 - $63M
    17 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.68---
    Sep 26EST
    		-$-0.79---
    Jun 26
    Reported Aug 6
    		$-0.80$-0.80+0.00%Beat+19.2%
    Mar 26
    Reported May 11
    		$-0.81$-0.90+10.00%Beat+26.4%
    Dec 25
    Reported Feb 26
    		$-0.83$-0.99+16.16%Beat+34.6%
    Sep 25
    Reported Nov 6
    		$-0.92$-0.98+6.12%Beat+31.3%
    Jun 25
    Reported Aug 7
    		$-0.99$-1.03+3.88%Beat+34.9%
    Mar 25
    Reported May 8
    		$-1.10$-1.27+13.39%Beat+1.8%
    Dec 24
    Reported Feb 27
    		$-1.27$-1.32+3.52%Beat+13.0%
    Sep 24
    Reported Nov 7
    		$-1.34$-1.37+2.19%Beat+2.9%
    Jun 24
    Reported Aug 8
    		$-1.52$-1.20-26.67%Miss-8.6%
    Mar 24
    Reported May 9
    		$-1.12$-1.36+17.65%Beat+4.3%
    Dec 23
    Reported Feb 22
    		$-1.46$-1.44-1.39%Miss-4.3%
    Sep 23
    Reported Nov 9
    		$-1.38$-1.50+8.00%Beat+7.4%
    Jun 23
    Reported Aug 3
    		$-1.40$-1.33-5.26%Miss-5.3%
    Mar 23
    Reported May 4
    		$-1.17$-1.38+15.22%Beat+40.3%
    Dec 22
    Reported Feb 23
    		$-1.40$-1.39-0.72%Miss-28.4%
    Sep 22
    Reported Nov 3
    		$-1.49$-1.25-19.20%Miss-53.6%
    Jun 22
    Reported Aug 4
    		$-1.33$-1.30-2.31%Miss-31.7%
    Mar 22
    Reported May 5
    		$-1.96$-1.11-76.58%Miss-184.1%
    Dec 21
    Reported Feb 24
    		$-1.09$-0.94-15.96%Miss-58.0%
    Sep 21
    Reported Nov 4
    		$-0.97$-0.85-14.12%Miss-106.4%
    Jun 21
    Reported Aug 5
    		$-1.01$-0.61-65.57%Miss-65.6%
    Mar 21
    Reported May 6
    		$-0.69$-0.66-4.55%Miss-9.5%
    Dec 20
    Reported Feb 25
    		$-0.69$-0.61-13.11%Miss-21.1%
    Sep 20
    Reported Nov 5
    		$-0.47$-0.57+17.54%Beat+4.1%
    Jun 20
    Reported Aug 6
    		$-0.61$-0.67+8.96%Beat-8.9%
    Mar 20
    Reported May 7
    		$-0.63$-0.42-50.00%Miss-28.6%
    Dec 19
    Reported Feb 27
    		$-0.57$-0.56-1.79%Miss-32.6%
    Sep 19
    Reported Oct 31
    		$-0.49$-0.61+19.67%Beat+7.5%
    Jun 19
    Reported Aug 1
    		$-0.56$-0.59+5.08%Beat-7.7%
    Mar 19
    Reported May 2
    		$-0.49$-0.57+14.04%Beat+3.9%
    Dec 18
    Reported Feb 27
    		$-0.43$-0.56+23.21%Beat+29.5%
    Sep 18
    Reported Oct 31
    		$-0.53$-0.49-8.16%Miss-20.5%
    Jun 18
    Reported Aug 1
    		$-0.52$-0.56+7.14%Beat-15.6%
    Mar 18
    Reported May 1
    		$-0.51$-0.56+8.93%Beat-41.7%
    Dec 17
    Reported Mar 14
    		$-0.61$-0.42-45.24%Miss-96.8%
    Sep 17
    Reported Oct 31
    		$-0.44$-0.49+10.20%Beat-
    Jun 17
    Reported Aug 1
    		$-0.45$-0.42-7.14%Miss-
    Mar 17
    Reported May 2
    		$-0.36$-0.35-2.86%Miss-
    Dec 16
    Reported Mar 14
    		$-0.31$-0.22-40.91%Miss-

    Key Metrics

    Valuation
    P/E Ratio-3.38EV/EBITDAN/A
    Price/FCF-4.34xFCF Yield-23.04%
    Profitability
    Profit Margin0.00%Operating Margin-1472.00%
    ROE-55.40%ROICN/A
    Financial Health
    Debt/Equity0.00xInterest CoverageN/A
    Current Ratio6.65xQuick Ratio6.65x
    Trading Statistics
    Beta1.80Avg Volume5.91M
    52-Week High$28.2552-Week Low$7.95

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$12.20
    SMA 20$12.15
    SMA 50$12.25
    SMA 200$12.99
    EMA 10$12.01
    EMA 20$12.11
    EMA 50$12.30
    EMA 200$12.65

    MACD

    Line: -0.10Signal: -0.03Hist: -0.07

    ADX

    ADX: 14.4+DI: 18.8-DI: 22.7

    Aroon & PSAR

    Aroon Up84.0
    Aroon Down100.0
    PSAR$13.23

    Bollinger Bands

    Upper Band$13.08
    Lower Band$11.22
    %B Position1534%(Upper)
    Band Width0.07

    RSI (14-Day)

    Neutral
    41.9

    Momentum Oscillators

    Stoch %K16.1
    Stoch %D37.1
    Williams %R-88.9
    ROC (10d)-6.4%
    Momentum-0.78
    CCI (20d)-153.5
    MFI (14d)69.4

    Volatility Measures

    ATR (14d)$0.76(6.7%)
    StdDev (20d)0.47
    Hist Vol58.5%(High)

    Volume Flow

    VWAP$11.42
    OBV34.2M
    AD Line-82.0M
    CMF (20d)-0.030

    Volume Metrics

    Avg Vol (20d)6.0M
    Vol Ratio1.1x
    VWMA (20d)$12.19

    Pivot Points

    R3$12.36
    R2$12.11
    R1$11.77
    Pivot Point$11.53
    S1$11.19
    S2$10.94
    S3$10.60

    Advanced Oscillators

    TSI-3.85
    Ultimate Osc45.1
    KST-9.38

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$7.66M$15.05M$23.02M$13.78M$14.24M$16.63M$12.87M$9.11M$6.96M$28.93M$-1,917,000$11.99M
    Cost of Revenue$0$0$6.01M$0$0$0$116.88M$0$0$0$2.47M$0
    Gross Profit$7.66M$15.05M$23.02M$13.78M$14.24M$16.63M$12.87M$9.11M$6.96M$28.93M$-1,917,000$11.99M
    Operating Expenses$120.42M$115.58M$121.73M$125.26M$124.24M$137.43M$149.32M$153.88M$146.00M$142.94M$138.07M$143.10M
    R&D$82.59M$80.74M$88.65M$94.75M$97.03M$108.43M$116.88M$123.38M$114.21M$111.85M$108.98M$113.70M
    SG&A$37.82M$34.84M$33.08M$30.51M$27.21M$29.01M$32.44M$30.50M$31.79M$31.09M$28.99M$29.40M
    Operating Income$-112,760,000$-100,532,000$-98,710,000$-111,477,000$-109,996,000$-120,807,000$-136,447,000$-144,770,000$-139,043,000$-114,003,000$-139,892,000$-131,107,000
    Interest Income$6.13M$4.30M$2.92M$10.15M$8.74M$6.48M$7.55M$9.06M$-7,932,000$6.57M$7.73M$8.88M
    Interest Expense$0$0$0$0$0$0$0$0$8.14M$0$0$0
    Income Before Tax$-107,424,000$-96,231,000$-95,744,000$-100,987,000$-101,659,000$-113,877,000$-127,138,000$-135,712,000$-147,183,000$-108,257,000$-127,532,000$-121,928,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-106,634,000$-96,231,000$-95,786,000$-101,324,000$-101,255,000$-114,329,000$-128,898,000$-135,712,000$-146,975,000$-107,436,000$-132,161,000$-122,224,000
    EBITDA$-112,082,000$-98,865,000$-93,479,000$-107,289,000$-109,593,000$-120,137,000$-137,483,000$-146,443,000$-141,301,000$-117,597,000$-139,104,000$-136,444,000
    EBIT$-113,550,000$-100,532,000$-98,668,000$-111,140,000$-110,400,000$-120,355,000$-136,447,000$-144,770,000$-139,251,000$-114,824,000$-135,263,000$-130,811,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about NTLA

    News

    Intellia Therapeutics names Jing Marantz as chief medical officer

    Intellia Therapeutics, Inc. has announced the appointment of Jing L. Marantz, M.D., Ph.D., as Executive Vice President and Chief Medical Officer, effective October 26...

    Investing.com•10/13/26•Somewhat-Bullish

    Intellia Therapeutics names new chief medical officer

    Intellia Therapeutics (Nasdaq: NTLA) has appointed Dr. Jing L. Marantz as its new Executive Vice President and Chief Medical Officer, effective October 26...

    StreetInsider•10/13/26•Somewhat-Bullish

    Intellia Therapeutics names Jing L. Marantz as new Chief Medical Officer to lead clinical and regulatory efforts.

    Intellia Therapeutics has appointed Jing L. Marantz, M.D., Ph.D., as Executive Vice President and Chief Medical Officer, effective October 26, 2026. Dr. Marantz brings over 25 years of experience in drug development...

    Pluang•10/13/26•Bullish

    Intellia Therapeutics Appoints Jing L. Marantz, M.D., Ph.D., as Chief Medical Officer

    Intellia Therapeutics announced the appointment of Jing L. Marantz, M.D., Ph.D., as Executive Vice President and Chief Medical Officer, effective October 26...

    Intellia Therapeutics•10/13/26•Bullish

    Price to earnings forward of Intellia Therapeutics, Inc. – BX:38I

    This article provides financial information for Intellia Therapeutics, Inc. (BX:38I) on the TradingView platform...

    TradingView•10/12/26•Neutral

    NTLA Valuation and Fair Value

    P/E
    -3.4x
    P/FCF
    -4.3x
    PEG
    -0.1x
    P/B
    2.1x
    See GNG's fair value

    NTLA Profitability: Margins, ROIC and FCF

    Gross margin
    100.0%
    Operating margin
    -1472.0%
    Net margin
    0.0%
    ROE
    -55.4%
    FCF margin
    -586.0%
    FCF yield
    -23.0%

    NTLA Competitors

    CompanyTicker
    Dentsply Sirona IncXRAY
    Novocure LtdNVCR
    Septerna, Inc. Common StockSEPN
    Azenta IncAZTA
    Personalis IncPSNL
    Biohaven Ltd.BHVN
    Trevi Therapeutics IncTRVI
    Nuvation Bio IncNUVB

    Sector: Healthcare

    NTLA Analyst Ratings

    Consensus
    Hold
    Analysts
    19
    Strong Buy
    1
    Buy
    9
    Hold
    6
    Sell
    2
    Strong Sell
    1

    NTLA Bull Case vs Bear Case

    Bull case

    • NTLA beat EPS estimates in 87.5% of its last 8 reported quarters.

    Bear case

    • NTLA's quarterly revenue changed -46.2% year over year.

    NTLA Earnings: Beat Rate and Next Report

    Beat rate
    7 of 8 quarters (87.5%)
    Average surprise
    6.9%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.79
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    2 up, 0 down

    Frequently Asked Questions About NTLA

    Does NTLA pay dividends?

    Intellia Therapeutics Inc (NTLA) does not currently pay a regular dividend.

    What is NTLA's market cap?

    Intellia Therapeutics Inc (NTLA) has a market capitalization of $1.67B with a current stock price of $11.34.

    Related stocks

    Sector: Healthcare

    All stocks starting with N

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In